Ibogaine is a naturally occurring psychoactive substance found primarily in the root bark of Tabernanthe iboga, a shrub native to Central Africa, particularly Gabon and Cameroon.
PIt’s a dissociative psychedelic with a uniquely long duration — a full experience lasts 18–36 hours.
It has been used for centuries in the Bwiti spiritual tradition of Central Africa as a sacrament in initiation ceremonies.
The biggest area of research interest is addiction treatment, particularly for opioid dependence.
Reports suggest ibogaine can dramatically reduce withdrawal symptoms and cravings, sometimes after a single dose.
It’s also been studied for alcohol, cocaine, and methamphetamine addiction.
The mechanism appears to involve resetting opioid receptor sensitivity and affecting serotonin and dopamine systems simultaneously.
It’s a Schedule I controlled substance in the United States, making it illegal to possess or administer. It is, however, legal or unscheduled in several countries including Mexico, Portugal, the Netherlands, and South Africa, where clinics operate legally. This recently has been changed to allow research.
Ibogaine carries serious medical risks, most notably cardiac arrhythmia — it prolongs the QT interval, which can cause fatal heart events.
Deaths have been reported, usually in people with underlying heart conditions or those using other substances.
Medical screening and monitoring are essential.
There’s also research into ibogaine analogs (like tabernanthalog and noribogaine) that aim to preserve the therapeutic effects while reducing cardiac risk.